Cargando…

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes

Epidemiological and animal studies have revealed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors suppress cardiovascular events in subjects with type 2 diabetes and atherosclerosis in animal models of diabetes. However, it still remains unclear if the anti‐atherosclerotic effect of SGLT2 inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwamoto, Masahiko, Kubota, Tetsuya, Sakurai, Yoshitaka, Wada, Nobuhiro, Shioda, Seiji, Yamauchi, Toshimasa, Kadowaki, Takashi, Kubota, Naoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201373/ https://www.ncbi.nlm.nih.gov/pubmed/35707828 http://dx.doi.org/10.1002/prp2.971

Ejemplares similares

Association between tear and blood glucose concentrations: Random intercept model adjusted with confounders in tear samples negative for occult blood
por: Aihara, Masakazu, et al.
Publicado: (2020)

Role of Insulin Resistance in MAFLD
por: Sakurai, Yoshitaka, et al.
Publicado: (2021)

Associations of sleep quality with the skeletal muscle strength in patients with type 2 diabetes with poor glycemic control
por: Hayashi, Takanori, et al.
Publicado: (2023)

Bi-weekly Glycated Albumin Measurement was Useful to Encourage Behavioral Changes in People with Type 2 Diabetes Mellitus
por: Aihara, Masakazu, et al.
Publicado: (2023)

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus
por: Nomura, Shosaku, et al.
Publicado: (2023)

Role of insulin receptor substrates in the progression of hepatocellular carcinoma
por: Sakurai, Yoshitaka, et al.
Publicado: (2017)

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
por: Li, Zi, et al.
Publicado: (2020)

Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes
por: Kakuda, Hirokazu, et al.
Publicado: (2019)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study
por: Kakuda, Hirokazu, et al.
Publicado: (2017)

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
por: Tobe, Kazuyuki, et al.
Publicado: (2017)

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice
por: Obara, Koki, et al.
Publicado: (2017)

Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
por: Nunoi, Kiyohide, et al.
Publicado: (2018)

The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice
por: Hanaguri, Junya, et al.
Publicado: (2022)

A xanthene derivative, DS20060511, attenuates glucose intolerance by inducing skeletal muscle-specific GLUT4 translocation in mice
por: Furuzono, Shinji, et al.
Publicado: (2021)

Chronic Intestinal Pseudo-obstruction with Mitochondrial Diseases
por: Jinnouchi, Takanobu, et al.
Publicado: (2021)

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2022)

Glucose level determines excitatory or inhibitory effects of adiponectin on arcuate POMC neuron activity and feeding
por: Suyama, Shigetomo, et al.
Publicado: (2016)

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
por: Suzuki, M, et al.
Publicado: (2014)

Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity
por: Kubota, Tetsuya, et al.
Publicado: (2018)

ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice
por: Edmunds, Shelley J., et al.
Publicado: (2019)

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2020)

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2021)

Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring
por: Kawaguchi, Yuji, et al.
Publicado: (2020)

Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice
por: Nakajima, Kenichi, et al.
Publicado: (2015)

Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19
por: Futatsugi, Hiroyuki, et al.
Publicado: (2020)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis
por: Murakami, Kentaro, et al.
Publicado: (2022)

Beneficial Effect of Glucose Control on Atherosclerosis Progression in Diabetic ApoE(−/−) Mice: Shown by Rage Directed Imaging
por: Tekabe, Yared, et al.
Publicado: (2014)

J-curve relation between daytime nap duration and type 2 diabetes or metabolic syndrome: A dose-response meta-analysis
por: Yamada, Tomohide, et al.
Publicado: (2016)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
por: Kaku, Kohei, et al.
Publicado: (2014)

Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial
por: Katakami, Naoto, et al.
Publicado: (2022)

Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss
por: Sato, Yuichi, et al.
Publicado: (2019)

1-deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin-induced diabetic mice
por: Li, You-Gui, et al.
Publicado: (2013)

Body‐weight‐independent glucose‐lowering effect of the β3‐adrenergic receptor agonist mirabegron in humans
por: Waki, Hironori, et al.
Publicado: (2021)

Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
por: Kubota, Yoshiaki, et al.
Publicado: (2022)

Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
por: Katakami, Naoto, et al.
Publicado: (2020)

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
por: Kamei, Shinji, et al.
Publicado: (2018)

The Association between Carotid Atherosclerosis and Glucose
por: Koo, Bo Kyung
Publicado: (2011)

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus
por: Higashikawa, Toshihiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1crh1h106od132me3a1l1e5j7d